The Experts below are selected from a list of 140424 Experts worldwide ranked by ideXlab platform
Michitaka Ozaki - One of the best experts on this subject based on the ideXlab platform.
-
A Novel Anti-Inflammatory Agent, 3-[(Dodecylthiocarbonyl)-Methyl]-Glutarimide, Ameliorates Murine Models of Inflammatory Bowel Disease
Gastroenterology, 2011Co-Authors: Nobuki Ichikawa, Kenichiro Yamashita, Tohru Funahashi, Shin Ichihara, Nozomi Kobayashi, Yasuyuki Koshizuka, Masaaki Zaitsu, Moto Fukai, Tomomi Suzuki, Michitaka OzakiAbstract:Objective and design To examine the effect of 3-[(dodecylthiocarbonyl)-methyl]-glutarimide (DTCM-G), a novel Anti-Inflammatory Agent that inhibits lipopolysaccharide (LPS) activation of RAW264.7 macrophages, on murine models of colitis and RAW264.7 cells.
Nobuki Ichikawa - One of the best experts on this subject based on the ideXlab platform.
-
novel anti inflammatory Agent 3 dodecylthiocarbonyl methyl glutarimide ameliorates murine models of inflammatory bowel disease
Inflammation Research, 2016Co-Authors: Nobuki Ichikawa, Kenichiro Yamashita, Shin Ichihara, Nozomi Kobayashi, Masaaki Zaitsu, Moto Fukai, Tohru Funakoshi, M Ogura, Tadashi Yoshida, Susumu ShibasakiAbstract:To examine the effect of 3-[(dodecylthiocarbonyl)-methyl]-glutarimide (DTCM-G), a novel Anti-Inflammatory Agent that inhibits lipopolysaccharide (LPS) activation of RAW264.7 macrophages, on murine models of colitis and RAW264.7 cells. Colitis was induced by rectally infusing trinitrobenzenesulfonic acid (TNBS) (1.5 mg in 50 % ethanol) in BALB/c mice or orally administering 3 % dextran sulfate sodium (DSS) for 5 days in C57BL/6 mice. The severity of colitis was assessed after intraperitoneally injecting DTCM-G (40 mg/kg). The Anti-Inflammatory properties of DTCM-G and its mechanisms were investigated in LPS-stimulated RAW264.7 cells. DTCM-G significantly ameliorated TNBS-induced colitis, according to the body weight loss, disease activity index, colonic obstruction, macroscopic colonic inflammation score, mucosal myeloperoxidase activity, and histopathology. Immunohistochemistry and isolated lamina propria mononuclear cells showed significantly reduced colonic F4/80+ and CD11b+ macrophage infiltration. DTCM-G significantly suppressed tumor necrosis factor (TNF)-α and interleukin (IL)-6 messenger RNA expression in the colon and attenuated DSS-induced colitis, according to the disease activity index and histopathology. In RAW264.7 cells, DTCM-G suppressed LPS-induced TNF-α/IL-6 production and enhanced glycogen synthase kinase-3β phosphorylation. DTCM-G attenuated murine experimental colitis by inhibiting macrophage infiltration and inflammatory cytokine expression. Thus, DTCM-G may be a promising treatment for inflammatory bowel disease.
-
A Novel Anti-Inflammatory Agent, 3-[(Dodecylthiocarbonyl)-Methyl]-Glutarimide, Ameliorates Murine Models of Inflammatory Bowel Disease
Gastroenterology, 2011Co-Authors: Nobuki Ichikawa, Kenichiro Yamashita, Tohru Funahashi, Shin Ichihara, Nozomi Kobayashi, Yasuyuki Koshizuka, Masaaki Zaitsu, Moto Fukai, Tomomi Suzuki, Michitaka OzakiAbstract:Objective and design To examine the effect of 3-[(dodecylthiocarbonyl)-methyl]-glutarimide (DTCM-G), a novel Anti-Inflammatory Agent that inhibits lipopolysaccharide (LPS) activation of RAW264.7 macrophages, on murine models of colitis and RAW264.7 cells.
Kenichiro Yamashita - One of the best experts on this subject based on the ideXlab platform.
-
novel anti inflammatory Agent 3 dodecylthiocarbonyl methyl glutarimide ameliorates murine models of inflammatory bowel disease
Inflammation Research, 2016Co-Authors: Nobuki Ichikawa, Kenichiro Yamashita, Shin Ichihara, Nozomi Kobayashi, Masaaki Zaitsu, Moto Fukai, Tohru Funakoshi, M Ogura, Tadashi Yoshida, Susumu ShibasakiAbstract:To examine the effect of 3-[(dodecylthiocarbonyl)-methyl]-glutarimide (DTCM-G), a novel Anti-Inflammatory Agent that inhibits lipopolysaccharide (LPS) activation of RAW264.7 macrophages, on murine models of colitis and RAW264.7 cells. Colitis was induced by rectally infusing trinitrobenzenesulfonic acid (TNBS) (1.5 mg in 50 % ethanol) in BALB/c mice or orally administering 3 % dextran sulfate sodium (DSS) for 5 days in C57BL/6 mice. The severity of colitis was assessed after intraperitoneally injecting DTCM-G (40 mg/kg). The Anti-Inflammatory properties of DTCM-G and its mechanisms were investigated in LPS-stimulated RAW264.7 cells. DTCM-G significantly ameliorated TNBS-induced colitis, according to the body weight loss, disease activity index, colonic obstruction, macroscopic colonic inflammation score, mucosal myeloperoxidase activity, and histopathology. Immunohistochemistry and isolated lamina propria mononuclear cells showed significantly reduced colonic F4/80+ and CD11b+ macrophage infiltration. DTCM-G significantly suppressed tumor necrosis factor (TNF)-α and interleukin (IL)-6 messenger RNA expression in the colon and attenuated DSS-induced colitis, according to the disease activity index and histopathology. In RAW264.7 cells, DTCM-G suppressed LPS-induced TNF-α/IL-6 production and enhanced glycogen synthase kinase-3β phosphorylation. DTCM-G attenuated murine experimental colitis by inhibiting macrophage infiltration and inflammatory cytokine expression. Thus, DTCM-G may be a promising treatment for inflammatory bowel disease.
-
A Novel Anti-Inflammatory Agent, 3-[(Dodecylthiocarbonyl)-Methyl]-Glutarimide, Ameliorates Murine Models of Inflammatory Bowel Disease
Gastroenterology, 2011Co-Authors: Nobuki Ichikawa, Kenichiro Yamashita, Tohru Funahashi, Shin Ichihara, Nozomi Kobayashi, Yasuyuki Koshizuka, Masaaki Zaitsu, Moto Fukai, Tomomi Suzuki, Michitaka OzakiAbstract:Objective and design To examine the effect of 3-[(dodecylthiocarbonyl)-methyl]-glutarimide (DTCM-G), a novel Anti-Inflammatory Agent that inhibits lipopolysaccharide (LPS) activation of RAW264.7 macrophages, on murine models of colitis and RAW264.7 cells.
Moto Fukai - One of the best experts on this subject based on the ideXlab platform.
-
novel anti inflammatory Agent 3 dodecylthiocarbonyl methyl glutarimide ameliorates murine models of inflammatory bowel disease
Inflammation Research, 2016Co-Authors: Nobuki Ichikawa, Kenichiro Yamashita, Shin Ichihara, Nozomi Kobayashi, Masaaki Zaitsu, Moto Fukai, Tohru Funakoshi, M Ogura, Tadashi Yoshida, Susumu ShibasakiAbstract:To examine the effect of 3-[(dodecylthiocarbonyl)-methyl]-glutarimide (DTCM-G), a novel Anti-Inflammatory Agent that inhibits lipopolysaccharide (LPS) activation of RAW264.7 macrophages, on murine models of colitis and RAW264.7 cells. Colitis was induced by rectally infusing trinitrobenzenesulfonic acid (TNBS) (1.5 mg in 50 % ethanol) in BALB/c mice or orally administering 3 % dextran sulfate sodium (DSS) for 5 days in C57BL/6 mice. The severity of colitis was assessed after intraperitoneally injecting DTCM-G (40 mg/kg). The Anti-Inflammatory properties of DTCM-G and its mechanisms were investigated in LPS-stimulated RAW264.7 cells. DTCM-G significantly ameliorated TNBS-induced colitis, according to the body weight loss, disease activity index, colonic obstruction, macroscopic colonic inflammation score, mucosal myeloperoxidase activity, and histopathology. Immunohistochemistry and isolated lamina propria mononuclear cells showed significantly reduced colonic F4/80+ and CD11b+ macrophage infiltration. DTCM-G significantly suppressed tumor necrosis factor (TNF)-α and interleukin (IL)-6 messenger RNA expression in the colon and attenuated DSS-induced colitis, according to the disease activity index and histopathology. In RAW264.7 cells, DTCM-G suppressed LPS-induced TNF-α/IL-6 production and enhanced glycogen synthase kinase-3β phosphorylation. DTCM-G attenuated murine experimental colitis by inhibiting macrophage infiltration and inflammatory cytokine expression. Thus, DTCM-G may be a promising treatment for inflammatory bowel disease.
-
A Novel Anti-Inflammatory Agent, 3-[(Dodecylthiocarbonyl)-Methyl]-Glutarimide, Ameliorates Murine Models of Inflammatory Bowel Disease
Gastroenterology, 2011Co-Authors: Nobuki Ichikawa, Kenichiro Yamashita, Tohru Funahashi, Shin Ichihara, Nozomi Kobayashi, Yasuyuki Koshizuka, Masaaki Zaitsu, Moto Fukai, Tomomi Suzuki, Michitaka OzakiAbstract:Objective and design To examine the effect of 3-[(dodecylthiocarbonyl)-methyl]-glutarimide (DTCM-G), a novel Anti-Inflammatory Agent that inhibits lipopolysaccharide (LPS) activation of RAW264.7 macrophages, on murine models of colitis and RAW264.7 cells.
Masaaki Zaitsu - One of the best experts on this subject based on the ideXlab platform.
-
novel anti inflammatory Agent 3 dodecylthiocarbonyl methyl glutarimide ameliorates murine models of inflammatory bowel disease
Inflammation Research, 2016Co-Authors: Nobuki Ichikawa, Kenichiro Yamashita, Shin Ichihara, Nozomi Kobayashi, Masaaki Zaitsu, Moto Fukai, Tohru Funakoshi, M Ogura, Tadashi Yoshida, Susumu ShibasakiAbstract:To examine the effect of 3-[(dodecylthiocarbonyl)-methyl]-glutarimide (DTCM-G), a novel Anti-Inflammatory Agent that inhibits lipopolysaccharide (LPS) activation of RAW264.7 macrophages, on murine models of colitis and RAW264.7 cells. Colitis was induced by rectally infusing trinitrobenzenesulfonic acid (TNBS) (1.5 mg in 50 % ethanol) in BALB/c mice or orally administering 3 % dextran sulfate sodium (DSS) for 5 days in C57BL/6 mice. The severity of colitis was assessed after intraperitoneally injecting DTCM-G (40 mg/kg). The Anti-Inflammatory properties of DTCM-G and its mechanisms were investigated in LPS-stimulated RAW264.7 cells. DTCM-G significantly ameliorated TNBS-induced colitis, according to the body weight loss, disease activity index, colonic obstruction, macroscopic colonic inflammation score, mucosal myeloperoxidase activity, and histopathology. Immunohistochemistry and isolated lamina propria mononuclear cells showed significantly reduced colonic F4/80+ and CD11b+ macrophage infiltration. DTCM-G significantly suppressed tumor necrosis factor (TNF)-α and interleukin (IL)-6 messenger RNA expression in the colon and attenuated DSS-induced colitis, according to the disease activity index and histopathology. In RAW264.7 cells, DTCM-G suppressed LPS-induced TNF-α/IL-6 production and enhanced glycogen synthase kinase-3β phosphorylation. DTCM-G attenuated murine experimental colitis by inhibiting macrophage infiltration and inflammatory cytokine expression. Thus, DTCM-G may be a promising treatment for inflammatory bowel disease.
-
A Novel Anti-Inflammatory Agent, 3-[(Dodecylthiocarbonyl)-Methyl]-Glutarimide, Ameliorates Murine Models of Inflammatory Bowel Disease
Gastroenterology, 2011Co-Authors: Nobuki Ichikawa, Kenichiro Yamashita, Tohru Funahashi, Shin Ichihara, Nozomi Kobayashi, Yasuyuki Koshizuka, Masaaki Zaitsu, Moto Fukai, Tomomi Suzuki, Michitaka OzakiAbstract:Objective and design To examine the effect of 3-[(dodecylthiocarbonyl)-methyl]-glutarimide (DTCM-G), a novel Anti-Inflammatory Agent that inhibits lipopolysaccharide (LPS) activation of RAW264.7 macrophages, on murine models of colitis and RAW264.7 cells.
